Robert Carlile, MD
Neurology · Summerville, SCNPI 1740575307
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $316,652 of the $427,525 with a category attached, or 74.1%. 60 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 37.8% of the total. 2025 is the largest year on record at $103,362, 2.6 times the $40,436 reported in 2019. Among neurology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,564 payments — averaging $166.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$162K
- AbbVie$141K
- Lilly USA, LLC$72K
- C2n Diagnostics, LLC$14K
- UCB, Inc.$5K
- Novartis$4K
- plus $29K from 54 others
Across 93 payments — averaging $20,590 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.2M
- Amgen$210K
- Eli Lilly$173K
- Lexicon Pharmaceuticals, Inc.$102K
- Astrazeneca UK Limited$97K
- Novo Nordisk AS$52K
- plus $62K from 2 others
What the payments were for
- Consulting fees$27,5636%
- Speaking & faculty fees$316,65274%
- Travel & lodging$41,80310%
- Food & beverage$41,32510%
- Education$1820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$427,525 in reported general payments places this provider in the 95th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RystiggoRozanolixizumab-Noli | 11 | $535,788 |
| AustedoDeutetrabenazine | 57 | $416,133 |
| IngrezzaValbenazine Tosylate | 37 | $309,001 |
| NortheraDroxidopa | 13 | $292,500 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 24 | $275,412 |
| NuplazidPimavanserin Tartrate | 50 | $272,180 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 12 | $206,952 |
| Kesimpta PenOfatumumab | 11 | $93,382 |
| RytaryCarbidopa/Levodopa | 42 | $81,509 |
| BotoxOnabotulinumtoxina | 65 | $76,733 |
| Emgality PenGalcanezumab-Gnlm | 42 | $54,211 |
| Nurtec OdtRimegepant Sulfate | 36 | $50,989 |
| QuliptaAtogepant | 31 | $49,806 |
| NourianzIstradefylline | 15 | $42,512 |
| UbrelvyUbrogepant | 26 | $41,667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Rystiggo | $4,901 | $535,78811 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $161,624 | $416,13357 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,096 | $309,00137 claims |
| Lundbeck LLCNorthera | $618 | $292,50013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $261 | $275,41224 claims |
| Acadia Pharmaceuticals IncNuplazid | $3,293 | $272,18050 claims |
| AbbVieBotox, Qulipta, Ubrelvy, Namzaric | $141,185 | $179,953137 claims |
| Amneal Pharmaceuticals LLCRytary | $664 | $81,50942 claims |
| PfizerNurtec Odt | $751 | $50,98936 claims |
| Kyowa Kirin, Inc.Nourianz | $446 | $42,51215 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $325 | $39,84721 claims |
| MDD US Operations, LLCGocovri | $870 | $25,69115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 270 neurology providers in South Carolina.
Other neurology in Summerville
- John LucasSummerville$31K
- John BakerSumter$779K
- Mary HughesGreenville$404K
- Jose CardenasAiken$216K
- Fredy RevillaGreenville$208K
- Robert AdamsCharleston$204K
- Thomas HughesMt. Pleasant$102K
- Kathleen WoschkolupGreenville$97K
- Sarah BreevoortCharleston$90K
- David HammettColumbia$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.